Persistent growth-promoting effects of vosoritide▼ in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life

Savarirayan et al. assessed the impact of vosoritide on growth-associated health-related quality of life (HRQoL) in children with achondroplasia. Data were gathered using the Quality of Life in Short Stature Youth (QoLISSY) questionnaire. Vosoritide improved self-reported and caregiver-reported QoLISSY physical and social scores, with the greatest increases being seen in participants with a ≥ 1 SD increase in height Z-score…

Vosoritide in children <2 years of age: Real world experience and practical tips – Webinar

For those of you who were unable to join us for this engaging and informative case-based webinar, the recording is now available on-demand! This webinar aims to provide you with insights from leading clinicians on the practicalities of vosoritide in children <2 years of age, including multidisciplinary team management, neurological considerations within the first year of life, a real-world case study and practical support for parents and caregivers.

Once you have viewed the webinar, we would like to know your thoughts on the content covered by our expert faculty. Please can you take 2 minutes to complete the survey at the link below:
https://www.surveymonkey.com/r/RFPKPGM

Anthropometric Measures in Achondroplasia

In this podcast, Klaus Mohnike, Diana Osmund, and Michelle Eagle discuss the varying approaches in clinical practice to measuring anthropometric measures in patients with achondroplasia, and review ways towards standardisation and why consistency is important for accuracy using case studies.

EU-ACH-00843